Efficacy lasts for 52 weeks and long-acting complement inhibitors reach the primary phase 3 clinical endpoint

On July 15, 2021, Alexion Pharmaceuticals announced that its long-acting C5 complement inhibitor Ultomiris (ravulizumab) has obtained positive results in a phase 3 clinical trial in adults with generalized myasthenia gravis (gMG)

The complement system is a part of the innate immune system.

Alexion official website pointed out that Ultomiris is the first approved long-acting C5 complement inhibitor.

This global randomized double-blind, placebo-controlled, multi-center phase 3 clinical trial enrolled 175 patients

In terms of safety, the Ultomiris group and the placebo group had similar adverse events

gMG is a rare autoimmune disease.

"The positive results obtained in this trial prove that Ultomiris has the potential to provide clinically meaningful effects for a wider range of patients

Reference materials:

[1] Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG).